Dopamine-β-Hydroxylase (DβH) activity
Following multiple-dose administration of zamicastat 400 mg, the
pre-dose plasmatic inhibition of DβH activity ranged from 19.8% on day
3 to 25.0% on day 10 (Figure 3) . The variability between
individuals was moderate, with coefficients of variation ranging from
32.6% to 39.8% during the 10 days of evaluation. With placebo, the
inhibition of DβH activity ranged from -3.9% (day 3) to -4.3% (day
10). Compared to placebo, zamicastat was associated with a statistically
significant increase in the inhibition of plasma DβH activity
(p<0.001) from day 3 up to day 10.